Barclays’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Barclays’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-14,185	Closed	-$37.7K	–	5433
2024 Q1	$37.7K	Sell	14,185 -383	-3%	-$948	﹤0.01%	4673
2023 Q4	$34.5K	Hold	14,568	–	–	﹤0.01%	4818
2023 Q3	$20.4K	Hold	14,568	–	–	﹤0.01%	4176
2023 Q2	$44.1K	Sell	14,568 -14,857	-50%	-$57.3K	﹤0.01%	3896
2023 Q1	$184K	Buy	29,425 +5,039	+21%	+$30.7K	﹤0.01%	3842
2022 Q4	$149K	Buy	24,386 +8,962	+58%	+$73K	﹤0.01%	4003
2022 Q3	$185K	Sell	15,424 -228	-1%	-$2.98K	﹤0.01%	3254
2022 Q2	$197K	Buy	+15,652	New	+$146K	﹤0.01%	3428

Barclays's KNTE Position: Q2 2024 in Review

Barclays sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 14,185 shares — an estimated $37.7K sold.

Barclays first reported a position in KNTE in Q2 2022 and held it in 8 quarters. The position peaked at $197K in Q2 2022. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

Barclays reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Barclays sold 14,185 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $37.7K.
Barclays first reported a position in Kinnate Biopharma Inc. Common Stock in Q2 2022 and held it in 8 quarters.
Barclays's Kinnate Biopharma Inc. Common Stock position peaked at $197K in Q2 2022.
0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on Barclays's 13F filing for Q2 2024, filed 14 Aug 2024.